logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
World Hepatitis Day 2024 | Collections | MSF Science Portal

Viral hepatitis is a significant cause of disease and death globally. Yet powerful new medical tools to combat hepatitis C and E still reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings.


To mark World Hepatitis Day (July 28th) we highlight recent MSF research on making these breakthrough products more widely accessible and simpler to use.


For hepatitis C, where groundbreaking antiviral drugs can cure nearly all patients, MSF is developing comprehensive, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. In some settings programs focus on the specific needs of highly vulnerable populations, such as people living in remote areas, forcibly displaced refugees, or those co-infected with HIV or TB or who inject drugs.


Turning to prevention, MSF is exploring ways to use the Hepatitis E vaccine more effectively in areas where poor sanitation and water quality regularly lead to outbreaks. Studies in a South Sudanese camp for internally displaced people are strengthening evidence for the vaccine’s feasibility, efficacy, safety and community acceptance, especially for pregnant women and their fetuses. Another report analyzes strategies for overcoming barriers to widespread vaccine adoption.

Collection Content

Conference Material
|
Abstract

First mass reactive vaccination campaign against Hepatitis E: main results of observational studies

Gignoux EM
2024-05-23 • Epicentre Scientific Day 2024
2024-05-23 • Epicentre Scientific Day 2024

BACKGROUND

Hepatitis E was first identified in the 1990s, but major epidemics date back to the 1950s. There is no specific treatment, and it can be fatal especially for pregnant...

Conference Material
|
Poster

Prevalence of active hepatitis C virus (HCV) infection and associated factors among forcibly displaced Myanmar nationals residing in camps, Cox’s Bazar, Bangladesh

Ashakin KA, Hadiuzzaman M, Firuz W, Rahman A, Ben-Farhat J,  et al.
2024-05-23 • Epicentre Scientific Day 2024
2024-05-23 • Epicentre Scientific Day 2024
Conference Material
|
Abstract

Safety of hepatitis E vaccine in pregnancy: emulating a target trial following a mass reactive vaccination campaign in South Sudan

Nesbitt R, Azman AS, Asilaza VK, Edwards JK, Nkemenang P,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION

Hepatitis E causes high mortality among pregnant women, with case fatality risks over 30% and adverse fetal outcomes. There is an evidence gap on the safety of the ...

Conference Material
|
Poster

Evaluation of a simplified model of care for chronic hepatitis C infection in Rohingya population in Ukhiya, Cox’s Bazar, Bangladesh

Firuz W, Ashakin KA, Schramm B, Camelique O, Duka M,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Journal Article
|
Research

Nurse-led initiation of hepatitis C care in rural Cambodia

O’Keefe D, Samley K, Bunreth V, Marquardt T, Bobi SE,  et al.
2023-04-01 • Bulletin of the World Health Organization
2023-04-01 • Bulletin of the World Health Organization
OBJECTIVE
To determine whether a nurse-led model of care for patients with hepatitis C virus (HCV) infections can provide safe and effective diagnosis and treatment in a resource-poo...
Journal Article
|
Research

A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa

Saayman E, Hechter V, Kayuni N, Sonderup MW
2023-03-04 • Harm Reduction Journal
2023-03-04 • Harm Reduction Journal

BACKGROUND

Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PW...

Journal Article
|
Research

Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study

Swe TM, Johnson DC, Mar HT, Thit P, Homan T,  et al.
2023-02-17 • Health Science Reports
2023-02-17 • Health Science Reports
BACKGROUND AND AIMS
In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplificati...
Journal Article
|
Commentary

Hepatitis E vaccine—Illuminating the barriers to use

Lynch JA, Lim JK, Asaga PEP, Wartel TA, Marti M,  et al.
2023-01-05 • PLOS Neglected Tropical Diseases
2023-01-05 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...

See more collections

Yellow fever

Yellow fever
No description available
MSF logo

Sudan/Chad Disaster
No description available
World NTD Day

World NTD Day

Neglected tropical diseases (NTDs) impact nearly 1.7 billion people each year, causing serious illness or lifelong disability among many—often leading to stigma and exclusion—and killing an estimated 200,000. The vast majority of sufferers live in the world’s poorest countries.


The World Health Organization’s NTD roadmap 2021-2030 aims to address 20 tropical diseases through prevention, control, elimination, and/or eradication. But despite some progress, reaching all its targets will take better, far more accessible diagnostics and treatments along with more robust strategies, political commitment and resources.


To mark World NTD Day, this collection spotlights work by MSF and collaborators on improving approaches to snakebite envenoming, kala azar and noma. One study presents an innovative artificial intelligence-based snakebite diagnostic tool, while others evaluate shorter, less toxic drug regimens or different models of care. Several commentaries advocate for national/regional strategies adapted to contexts ranging from remote villages to active conflict zones. Another crucial factor is the climate crisis, which is intensifying the transmission and geographic spread of many NTDs.

View All Collections
World Hepatitis Day 2024

World Hepatitis Day 2024